Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 28-34

  Caslake, Muriel J ^a   Packard, Chris J ^a   Robertson, Michele ^a   Cooney, Josephine ^a   Nelson, Jeanenne J ^b   Ford, Ian ^a   Gaw, Allan ^c   Jukema, J Wouter ^d   Macfarlane, Peter W ^a   Stott, David J ^a   Shepherd, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coronary heart disease risk; Elderly; Inflammatory markers; Lipoprotein associated phospholipids A2; Prosper

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPID; LIPOPROTEIN; PLACEBO; PRAVASTATIN;

AGED; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEINS; MALE; RISK FACTORS;

EID: 77952423747     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.041     Document Type: Review

References (30)

1. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-II10.
2. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
3. Mora S., Rifai N., Buring J.E., Ridker P.M. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 2006, 114:381-387.
4. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006, 166:1368-1373.
5. Madjid M., Awan I., Willerson J.T., Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004, 44:1945-1956.
6. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001, 358:971-976.
7. Rosengren B., Jonsson-Rylander A.C., Peilot H., Camejo G., Hurt-Camejo E. Distinctiveness of secretory phospholipase A(2) group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta 2006, 1761:1301-1308.
8. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
9. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
10. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006, 26:1586-1593.
11. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
12. 2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:527-532.
13. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
14. 2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159-165.
15. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003, 41:37S-42S.
16. Chen C.-H. Platelet-activating factor acetylhydrolase:is it good or bad for you?. Curr Opin Lipidol 2004, 15:337-341.
17. Ford I., Blauw G.J., Murphy M.B., et al. A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): screening experience and baseline characteristics. Curr Control Trials Cardiovasc Med 2002, 3:8.
18. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
19. Packard C.J., Ford I., Robertson M., et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2005, 112:3058-3065.
20. Sattar N., Murray H.M., McConnachie A., et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007, 115:981-989.
21. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004, 110:1903-1908.
22. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005, 26:137-144.
23. 2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005, 2:529-535.
24. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479-2484.
25. 2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006, 27:2346-2352.
26. 2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005, 25:216-221.
27. 2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006, 26:106-111.
28. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
29. 2, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073-2080.
30. Nambi V, Hoogevenn RC, Hu LCY, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study, vol. 40. American Heart Association Inc.; 2009. p. 376.